You are here

HTG Molecular Announces an Amendment and Extension to its Precision Diagnostic Partnership (PDP) Two

TUCSON, Ariz., Feb. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it has amended its second precision diagnostic partnership program (“PDP Two”) with QIAGEN Manchester Limited (QML) originally signed in October 2017. This fourth amendment to the program extends the use of the investigational use only (IUO) assay previously developed as part of the program, and adds certain activities that potentially could be included in future companion diagnostic regulatory submissions. The program amendment is expected to generate revenue in the low single-digit millions for these additional activities. HTG expects to complete the activities related to this amendment in 2019.
Wednesday, February 20, 2019 - 16:01